Bellicum Pharmaceuticals (BLCM) 7 Aug 182018 Q2 Earnings call transcript

Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to the Bellicum Pharmaceuticals Second Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time.

conference recorded this replay. available reminder, a will and be for As would to Financial Bellicum’s you to Officer. host I introduce Musso, our like today, Alan Chief Please go ahead.

the and Thank results Bellicum’s Fair, for released ended Officer. Chief Bill quarter you afternoon, Earlier Roya. and and me June everyone, the Officer; Chief you, for is second Good President joining XX, financial Grossman, call. Executive Rick this With today Bellicum thank XXXX. Medical afternoon,

you Investor not would the website. have If of received added can or if the to this to like you distribution do release be so Relations Company’s you list, on the page

section to to quarterly report Commission. XXXX Actual our the XX-Q on Report Rick. over Form outlook. by filed As a development trials, call. due our new year of plans our light statements forward-looking Reform made Exchange Litigation or and future of statements Act Securities factors, expectations statements Form reminder, ended Annual of on release the review this I’ll including of as financial those our a And information commercialization regarding only XXXX, to obligation product numerous regulatory the and uncertainties to opinions the plans, events. XX-K These forward-looking our for candidates, the clinical turn filings, – and of results in June Factors of with quarter reflect June regarding or revise today’s number call these We for no in and now ended XX, and call include forward-looking including revision results any approval Risk the publicly research undertake Securities from these differ statements will date may risks under Private the of statements and indicated conference involve our forward-looking discussed those of the

and developments BPX-XXX, later everyone. the enter genetic our is quarter. lymphomas leukemias, our this for diseases, with its continues therapy and data afternoon, lead to have CAR-T patients to on made on blood advance controllable development report Overall, first BPX-XXX, Good market in allogeneic track Alan. initial to year. cell this programs Europe. T-cell with therapy path Thanks, we to substantial progress clinical

made our balance Including development clinic the XXXX. of the of our important like we little enter advances with also to progress, GoCAR-T I’d BPX-XXX. switch with We candidates with pipeline. technology, starting a color the to our on two dual more give expect which in

the in read in As blood our press in pediatric today, and C-XXX you enrollment with release have studies hematologic patients completed may disorders. BP-XXX in cancers perspective we inherited orphan

studies a receiving We is transplant. basis as for expect matched trial C-XXX a that Europe. observational filing or of these multicenter, unrelated in the pediatric donor will serve MUD patients

can who that If bode least at achieve will our BPX-XXX patients, an good will not is of clinically comparative XX% currently service donor. do months, patients study, well HLA analysis a as approximately the transplants goal primary a for option We to for success. MUD lead free a as matched to and be the outcomes receiving trial comparison as for a MUD are are demonstrate without of preferred following be this patients sibling transplant we transplant. The donor, receiving non-inferiority. to MUD versus at matched of the and haploidentical transplant, BPX-XXX those six meaningful very have event a the enables demonstrate the would conducting study commercial BP-XXX survival

the treat studies for both BP-XXX steroid from patients outcomes event interest, available subsets free Hematology applications of the received C-XXX, are survival December, authorization of including to of Meeting Annual in clinical marketing of to patients in BP-XXX the early BPX-XXX in from from expected a to abstracts rimiducid We’ve a goal and with submitted both to American Society rimiducid form both as update disease and filing on forward present and XXXX, GvHD. C-XXX results the results and comprehensive looking We’re experience who BPX-XXX. some Europe refractory be interim XXXX. Final in

addition to toward malignant of pediatric potential In working adult these extending studies, patients. the to BPX-XXX we’re benefit clinical

this which and We compared eliminating were to reducing believe we for a transplant. cancer XX repertoire study this with leukemias, X of and a at year, the cancer Based who we’ve of broad pediatric contain results AML approximately median T Phase X, and be XX% available As cells, following pediatric reported EHA protocol in overall residual following respectively, months. in adult believe BPX-XXX submitted earlier such why effective durable a in strong be BPX-XXX seeing designed and survival on the FDA therapies. are highly has relapse-free may and review. or we’re patients, polyclonal follow-up cells a at received when responses cells, transplant diverse fighting may AML We XX% to the

this initiate by for the in to avenues planning U.S. explore patients continue an year. of pediatric the We’re in We’ve end the secure approval also potential to BPX-XXX trial to

conducting As the in in we’ve single U.S., registrational evaluating previously been a communicated, ultra orphan indication. the a feasibility of pediatric trial

less assessment current to expand the portfolio. timeline of such attractive and a than cost, other Our study, value our it of makes opportunities

starting the orphan now. held Thierry Zogenix, data ground has leadership recently update for that, through in we’ll Darcis, like team we General turn in products be registration our has if Thierry approval Pharmaceuticals Also and programs and ViroPharma. CAR-T you his in with Thierry then. and this to I’d U.S., With launch efficient yesterday, prioritization roles de-prioritizing with to from in lag the revisit commercial to also and XXXX recruiting our BPX-XXX. intend announced Europe we’re Manager and our XXXX. instrumental experience he’ll the of He built-in to and our NPS BP-XXX efforts. operations Europe. the was to confident and as products plans BPX-XXX running with welcomed for European Dr. and find pediatric and extensive file to new FDA, launching for pediatric study and And we TCR We hit new review study attractive dialogue, pre-commercialization in GlaxoSmithKline. initiating previously a an Novartis launch I’m path updated has So

you and CAR-T product the first first know, GoCAR-T human As is to candidate controllable BPX-XXX enter cell our studies.

T-cell We IMC enhance be modulate and switch. the as our continue and to excited the designed proprietary targets as equipped BPX-XXX IMC tumor to it’s the of microenvironment PSCA, potential with immune to well about platform. activation GoCAR-T activity. drive to proliferation is is

go dose the and with use. its activated leverage rimiducid. in cell optimize the the schedule will lot. As a small IMC, learning this these Particularly, therapy human our of is And we’re experience as first we learnings molecule to

and cancer, an year. to to from report cancers the it dose to utilize We medical treat meeting continue standard enroll published and findings escalation regimen. I at study to phase of more safety preliminary and recently We the later in study conditioning in the and cell Phase a amendment the expand gastric this patients expect pancreatic prostate study to to

expect patients the additional to the enrolling sites this expand third study the begin of to We under through quarter, year. the amended remainder in and to protocol

patients affinity continue with to high our we T-cell center, at PRAME, targeting single a recruit BPX-XXX, receptor AML to and MDS. Turning

progression to be the for and study Enrollment Given expression of require advanced test been both patients slow. PRAME the in as patients. to matched, eligibility these which has HLA-AX the well positive criteria, AML rapid as

clinical several the type of be process if the adding in study, We’re PRAME additional to additional should expression evaluating included. sites and tumor

XXXX. be in to clinical present to results study the expect this initial We year, enrolling patients from sites the new later in and intend

from our our beyond operations clinical facility. We pipeline build full transfer what out and clinical Looking up rest validation technical year-end. our to we the of achieved for to organization, production trials the BPX-XXX I’m early Having currently has ramp BPX-XXX and well-positioned commercial Houston of BPX-XXX therapy our projects intend capabilities. team able and our of recently to to more continues produce trials, thereby cell are GoCAR-T to team deliver. supply. U.S. manufacturing there, new sites been production And proud

projects. been technologies, both essentially a pedal next-generation has with potentially safety team gas advancing providing both research and the switch break Our have safety. our and efficacy been busy designed activation also enhance GoCAR-T to These and

initiate for two products expect for at work, submissions, trials hard We’re IMPD to dual XXXX. in GoCAR-T preparing IND switch and new and clinical

we Bellicum. of overseeing Shane to On in Thierry appointment GM Europe, than Darcis’s of Secretary Shane as and more to legal, on welcome teams Ward companies. Corporate small years the recently addition biotech personnel has and of front, experience, QA large public both and Counsel and XX General as pharmaceutical compliance

the our all our of employees dedication behalf to contributions take on of and significant and Alan opportunity company. his Musso, to I’d board, thank this our many Finally, CFO, to like

best. will for very replacement. miss that, be opportunity his our Accounting the quarter back Next him Controller as Finance and to Interim while of month, the move wish as a of Alan’s cover Williams, will Alan new hand [indiscernible] & and will look we financials. call I’ll by all second Alan Officer, our VP he’ll we onto he With Principal serve Rosie

second in XXXX. Thank June million ended $XX.X compared second loss you, comparable for and $X.X $XX respectively, and million and The million $X.X results XX, share-based months and for ended $X.X net and million periods comparable June of of six $XX.X XXXX, a loss of the the XXXX. $XX.X non-cash, XXXX, quarter the the Rick. the of $X.X months charges for million included reported and of six million XXXX Bellicum to periods million net for XX, quarter million compensation for a

June $XX.X will the requirements on $XX.X restricted expenses respectively, and to expect General for cash June and the periods now and over the $XXX.X and June in And resources XXXX. six investments expenses for $X.X operating totaled XX, million administrative million three million, cash ended Based and $XX.X continues through XXXX. $XX.X to million be million million XXXX, the XXXX, and periods $XX XXXX, comparable plans, Research months current and months to during call of comparable you. As XX, I’ll million. hand million in ended respectively, six $X.X XX, to and during were $XX.X back sufficient the compared meet that Rick, development and million XXXX. three compared to were current Bellicum cash, operating

Alan. Thanks,

from As all comparative present milestones We’ll for analysis we’ve and the a a the late BPX-XXX productive heard, year and C-XXX BPX-XXX. had broad December with the of important of half you’ve from both with both studies. data over in set BP-XXX six interim program next first BPX-XXX months coming

II We also adult expect trial in Phase our AML. initiate three to

the BPX-XXX to We in call out open of questions. Phase to to cancer report controllable therapies. to we look forward quarter. treatment through the continue cell I the Our fourth with up trial transform expected work strive ahead, as is I’ll now to

question-and-answer [Operator be session. now We’ll you. Instructions] conducting Thank a you. Thank

proceed. of will line Karnauskas Citi. Our with the Robyn from come first question Please

question. the the Is the Hi guys, any this previous additional any all with on And Robyn. is you cells? update patients, Greg or Harrison progress. on there BPX-XXX for maybe taking cells of re-dosing have said expand Congratulations dosing you that again? to on levels you the able Thank from are the longer-term gained patients insight for

the Yes, for thanks, question. Greg

report of we’re the with We results this haven’t be we’ll BPX-XXX, clinical study disclosed quarter To in of the single to any study information biomarker per date, fourth year. question, wait rimiducid. both of additional your to a clear only dose about in dosing and though, the to protocol date,

So is the study. escalation mind, safety this keep in dose

dosing at We cells plus multiple rimiducid consider this stage, of doses that but safety advanced cells. we’re the dose of the rimiducid, if and are of would single evaluating we stage, a the we of past certainly, safety ones. The the

great. Okay,

Just set a the cancer amendment and timeline will expand prostate quick to the gastric patients trial? of How to follow-up. be

a the on in signal phase. tumor expansion based first with possibilities those types, different Phase study X the It’s into

to pancreatic that continue of study, of the we see. results paused But it study cancer, So escalation we so change course, we the portion. enroll continue dose on general the shouldn’t haven’t depends we the readout the

you. Thank Great.

you. Thank

Biren Our of Amin Jefferies. proceed. next question comes Please from with the line

thanks BPX-XXX a Can Hi bit? that guys, I little Rick, for mentioned utilizing you more regiment. about my are you Yes. amendment for think the talk a depletion for that taking questions. you standard

Sure, happy to.

the in around that that experienced their we with time they you were recall JCARXXX launching fludarabine. study that were have trial. associated at So time, may several BPX-XXX debts the And this was deaths those time hypothesized

initiate to a As only that study conditioning. cyclophosphamide had we agreed the using time result, with FDA at the

room been amending trial that expand. and back we’re the if into As dispelled, GoCAR-T – hypothesis for cells more fludarabine has for to call to want enhancement the fludarabine regiment that, conditioning it now to the our re-include depletion create you largely to

once yes, you influence potentially potentially guess, I think cell do that trial? the that, have And that persistence see in you also you would could

could. It

screen it failure What’s seems been full BPX-XXX, then the in on the rate you’re And enrollment. it. Got experiencing trial?

XX%, screen would been Yes, be And of think of positivity that, than XX% we’re or PRAME rates to then assessment something they terms match. I our don’t failure like reporting XX%, course, of less has I need exact expression. but say PRAME in HLA-AX

that that these are the of progress The So patients patients the is piece I’ll majority advanced they out that study. reiterate, quickly. AML screening on and commented I only are of other then very

And certainly be study a didn’t had who to treated. so patients but we qualified of enough long the for number survive

you. Thank it. Got

Thank you.

question the Our Birchenough next at live Please with your proceed. comes Jim Jim of line from now Wells Birchenough line Fargo. conference. is

muted on has it So end your sir.

sorry. Hello,

hear now. you Hello. Hi, we

that’s to and filing Slide coming X with it something rate up is on than that in, analyzing packaging in Bellicum, right, the just limiting Rick. data Although Anyway, all XQ, MAA? the for the other

rimiducid. PK data additional some also We’re on gathering

the to bring the analysis the application. main and datasets the and package. are then preparing So piece it’s need those of into that’s the But about we that doing three data other

Okay.

doesn’t that the that PK on too So those sound data…

will Bill is but… magnitude that two the onerous, of filing think of suggest that I MAAs

That I for remind analysis? No. free part you months your survival event event of And agree, six the us yes. definition can

on to Bill Are there? comment you that? Sure. want you

there. Yes, I’m sorry. on the was I mute

on So event – survival… free the U.S. be on disappear the

What’s definition event? Yes. of the

have It malignant severe survival well months, be severe look free relapse event for will non-malignant and infections. as as relates we’ll graft-versus-host-disease for to patients survival disease survival, free as free it six at

defined graft-versus-host-disease X severe if Grade And above? and as

Correct.

similar thank severe there you. for is great, infection? Okay, And definition

X. That would be Grade

well. know then is you and presenting longer in do update And collaborators X, you know CDXX that that Grade – program you. year for later on the control I Italy as an great, but and no the expected CAR-T, to me thank be on also this

clinical you’re This the or… referring ablation is – to

OPBG…

was OPBG time. it one BPX-XXX – I guess

It’s a different CAR-T, right.

construct CDXX with old switch. So CaspaCIDe Bellicum. an OPBG It’s CAR homegrown it’s a not safety developed from

you – go And expect them Okay. do ahead…

am presenting ASH they’re this Bill, do if year, you aware. at know I not

they abstract Yeah, six I year, as this sure sure. know that’s EHA, have do am patients am not today we I if submit – they but present an they not different

very look you thank great forward okay, much yeah, Yeah, and to…

Thanks Nick.

you. Thank

Our next Please proceed. question Li Wangzhi line the of Ladenberg. from comes with

just will my the I readout be for in quarter? taking for guess questions. ESMO is the questions, one two BPX-XXX. first Thanks Maybe like data number or

BPX-XXX be The readout that’s current I-O December our will in Geneva and ESMO in at plan.

would being Of submit get approved, course, be but our we abstract intent. it to that have an

number we any cancer? patient got Okay, And or patients the see maybe pancreatic we of cancer where it. color new with the on and and some see also old gastric prostate

talked Yeah, we’re and received rimiducid. cohorts not previously cohort first received followed present who couple XXX of cells commenting who by on specific cells patients only patients enrollment at figures, a but we have as BPX-XXX of least of we about have the will then

Okay, got it.

the timing would be And adding cancer amendment the I that given data largely exclusively would or others. expect the of pancreatic patients

Understand, just inspection wonder data? the I definition okay, you about kind then great. of the just more data that event And BPX-XXX, are ASH, going to see mentioned we details the

the the our is show as to in survival that of graft-versus-host-disease the be you all all study – would aspects in if event-free from reconstitution both of study which the mortality of as BP-XXX MUD. treatment intent will well study our observational Yeah, of beyond immune

first So we studies a comparison. opportunity both will be present that have end cross-trial points to of the time those an from for

correctly it. like Got arm remember I is the XX patients? And MUD if

date arm No, the enrolled patients. XXX to has over MUD

because than retrospective number had we we accrued of over little a in that patients study We’re a larger expected.

same it’s BP-XXX we in So the as over patients an conducted a in same study time reminder, period. MUD observational the centers

some period, get we of to the had to a same retrospectively, prospectively back also which portion enrolled. So XXXX collect cases we was patient in that to had time order

XXX-ish to report ASH. on would patients at expect we to able So be

XX combined but enrolled for over the I patient and right, XXX. about it member we of get prospects yes, mean Yes, all to is then retrospective patients

patients Yeah, neighborhood. that’s we accrued in a little bit XX less than that correct

MM… got is close Great given question, development update were specially Okay, any on final it. you BPX as maybe to and the PBX for front,

Yeah, can with do partner but partner. in that publicly. right do are we more platform with collaborations the these thanks interested remain collaborations. in active. We things certainly think opportunity right remain for we difficult to to comment the the nothing question. the the discussions And I are welcome predict, interested on and would could with our We Obviously, and we

just to go I question mind. my more one Okay. coming

For manufacturing want if that mentioned to GMP now the it are [indiscernible] correctly. you PBX-XXX PBX-XXX you right just and manufacturing hear facility, transfer I your own I PBX-XXX facility next in and expect year, in to the verify you manufacturing

year, this be so and hear all XXX the for year, we Later making of by XXX end U.S. the the XXX, trials. will

congratulation for right taking quarter. the and the on All great. thanks of questions my Okay, results

Thank you.

Thank you. Fitzgerald. Justin comes Kim proceed. question the line of with from Please next The Cantor

evening. Good

the on Just level year, or the completion. would data at one the from pace the we contrast the in the of data, of me. study of Based the compared you on early as XXXX? full Could qualify size our of with enrollment near observe end

couple think But I the from study patient's that. final expect we information enrollment analysis the the dataset we of interim of of a ASH. at after so quantify majority the don’t the expect presentation, the be ASH will would months can part I

Okay, great. Thank you.

you. Thank

Robinson of question the comes with Pete proceed. next Our Lawson SunTrust Humphrey. line Please from

taking for questions. Thanks my

where always you, out thinking with be should team? additional Alan. to at and pleasure for senior are hiring build firstly, move. the process you be next wishes as we Just hires best the just, And a it’s about the levels been what Rick, you And

Or entire What additional organization; the in is question? senior the your that hires hire? level CFO

Yes.

months? thinking process, the over in of thinking you’re senior that be kind should we the XX where hire of kind CFO firstly, what levels additional Just about next about

Sure.

keep but and – the part to very so recruiting in interviewing process. recruiting relates posted and certainly you we'll active of the active CFO, it as So interviewing,

beyond, that executive staffed building senior we leadership is the say, beginning of think the major Thierry Affairs, that to build our Managers on and of team there. top other in of course, fill I the to out a place he's need. senior to additional identifying think Medical the of for that hires in I relates we it I lot progress made Access, we have in would of markets Commercial Head of terms in BPX-XXX, team CFO role, he’s his once commercialize hires, team right General Head be Market the talent, Head out will Europe As of

So that's XX be of that. hiring focused probably on the will next X to months

the to that adult did the just expansion? What And see that do Thank you. expansion that drove pediatric the then what And see AML. on point drove you we that data that leukemia in at expression?

adult question the why are What Your about the do into in going we pediatric see data? AML. we

What kind expansion. pediatric the been and exactly. comments have encouraging Yes, data in opening mentioned of did leukemia you – about the

Yes, sure.

data XX% we've to more between to the So meaningful of continued terms leukemia suggests survival of certainly I at months leukemic could we've follow-up overall we and literature The confident relapse-free as relapse. AML, in preventing which pediatric as think of where be follow-up, it's XX% that to follow survival longer. and from months subset seeing we're say average, XX%. you're get that sort XX%. had of is confidence one our BP-XXX of little with overall XX.X year a had read presented six of EHA on survival In of When what in hard

challenge course, would relapse time manageable. I and impact course we disease seem myeloid leukemic – say donor role So particularly meaningful or can where for that have in extending lymphocyte's setting. of T And a giving reference approach also some of having it's valuable robust and on fighting an The we that fusion a been can that well in play is, meaningfully we in survival think was cells we make be delaying leukemias. donor relapse that established to terrible

impact cells about into AML, are outcome I donor we in adult So literature in donor BP-XXX, T confident of of moving the feel great think the cells the so what's and based on for the in known T importance setting. potential the

for I that? the Rick, and leukemia, this. when Pediatric readout missed we I get apologize next if is

ALL patients, subset. leukemic an so We've the includes both pediatric ASH, that to submitted whole AML abstract pediatric and

will if that you see So accepted. it’s in ASH

so you Thank for Thanks Perfect. taking much. questions.

Peter. thanks, Yeah,

you. Thank

Our question Raymond with Reni the Please next proceed. comes from James. Benjamin line of

taking I you activities? you talked the guys. the have, Rick, afternoon, that jumped a might little kind ton of how little like the a reasons, talk a questions. a prelaunch for you as the And good unfolding? Thanks about can so I call sense for of have competitive if to I you you've you about this everything, of talk us to can And late, Hey, bit you apologize. give Zalmoxis like and launch assume a done on there. learnings as be contrast probably comparing able not and while about see this there’s But

comment preparations say out Sure. it's got on that the we to because all date is questions, until primary I'm when disappointing launch I those days answer to and to that not early commercial going we've that lay would a out. prepare. XXXX lot from Zalmoxis you our need to away take

now conditional I I approval job of there successfully getting pay to a think with nice year based collaboration is collaboration the that limited it pay data think very of on the set, that to no but established little the least commercialize unfortunately, satisfaction down to publicly preparation And report with seems, product more a than – a start they’ve get approval. a did at team with was already. they bit after information late there down that started

where you do products have actually are the how to he’s well with it. Our several products view companies, Darcis assembling know Thierry successfully and orphan is, great commercial for data great prepared. successful they and happen lunches team launched

our Europe preparations the get a well experience clinical be as of they we’ll leader thought dossiers product reimbursement launch. it We make and will closer great years we more about we our our I’m prepare engaged and community, confident, evolve and a thought couple amongst to as we to with in health leaders success. earnest, approval talk We’ll beginning have we’re certainly economics we we will to an in have prepared, have will Europe comes have will and the

talk we Okay. a question. seems we specific. tends with protocols, it at which hearing related different certain you do is just And then correctly? like transplant conducting When certain decide, color Are type maybe just things center be us there facilities, as be it assume How transplanters about they that Can I’m that? facilities there. transplants, little alpha-beta a to to target? all more as how you have give bit but are I to depletion wrong to you thinking

broadly across really do if on transplanters Transplanters as transplanters product your a my So research see are at absence hear I approaches work market your a adopted they adult accurate, well approach and them. transplant and variety for there was of interim that example is the adapt U.S. been and I developed think now think would approach Europe. succeeds comments are there my was is, in transplant analyses. when really about from trends, standardized Hopkins based by target can good that you labels real to a transportation That adapt we change on adoption the is and they facility said, tailor can profile, but the the try what of as our in what that. adult has me think cyclophosphamide, guidance our I their setting which increasingly so show product which based in for that data, in post I transponders

done probably think facilities other those and that. a supports an take opportunity will the transplant already course, alpha-beta pretty and add adopters. view depleted penetrate XXX That’s and yet there’s step sort we it. be be adoption that a to T-depleted Our there research But T-cell to will facility or our doing of easier haven’t early that’s much simple simply they where to is sequencing haplo’s, of certainly, phasing is haplo

sense you facilities the U.S. those – have early of are adopters. could just do in a EU proportion versus what And be

Yes.

using as that T-depletion So I a the it’s in new speak we’re for alpha-beta trials. not and only his – only certainly clinical in and has Thierry been so approved team. profiling approach project reserved say that’s for would it’s U.S. in we Europe

centers here as experience be that. certainly adult limited. clinical Certainly the AML, is more with for rollout an to So there more experience more we U.S. gain opportunity of will

many one I the then the I’m end getting study just mentioned cohort we you in Can how versus be at don’t the patients, ASH know in to MUD. will And for observational year non-malignant. one always it. And Got XXX at think tell the about study just a number me. just the looking I of previous patients final at of in is the malignant you us, question wrong.

Bill, nail do number the patients in BP-XXX you of and and – between have malignant a some split on non-malignant. rough

The we’ve on have XX have for patients I it leukemia to split and patients between malignant quick we and real portion. up that in non-malignant AML that reported look have AML we’ll roughly XX

what expect set our that’s see the to So total you as fraction, in of not quite patients. would

it’s sounds that’s Bill’s I about XX-XX split in So malignant, saw from and the total analysis that comment so you’ll will be the range XXX non-malignant, see. about of I think what last at was

very Perfect. Thanks guys. much

You bet.

our floor for reached Mr. We’ve closing the session. remarks. Rick of end to you. hand me Fair back over the Q&A to Thank Allow

today. Thank you, Roya and thanks everyone participating for

clinical efforts day. importantly the I’d who like Thanks in patients well our always, families and team, As Bellicum a great for evening. They every our investigators our effort participated and and collaborators have trials. their thank as to have our inspire

Thank This you. today’s concludes conference.

You may thank disconnect time your you at participation. lines this your for and